Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipranavir/Ritonavir PK in Hepatic Insufficiency
NCT02249442Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2003
- Primary completion
- Jun 2004
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of tipranavir in human immunodeficiency virus infection (HIV), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration time curve from 0 extrapolated to infinity at 12 days, Area under the concentration time curve from 0 to 12 hours and 2 more. Started Oct 2003; status: completed.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02249442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02249442.